西部制药服务
WST
384.02
+1.00
+0.26%
西部制药服务
US · WST
#752 按市值排名
上市于 1970
384.02
+1.00
+0.26%
实时 - 追踪5344个代码 - 心跳于15秒前
· 2026-10-16 19:30
✦ 量化财务健康度 计算方式说明
良好
- 奥特曼 Z 值为17.84，高于3.0的"安全区"阈值。
- 该模型对工业和制造业公司最为可靠，对银行、保险等金融类公司参考意义较弱。
营收 年度数据，近8年
最近年度同比+6.25%
利润率
- 毛利率
- 35.91%
- 营业利润率
- 20.69%
- 净利率
- 16.06%
关键比率与质量指标
奥特曼 Z 值低于约1.8提示财务困境风险，高于约3.0提示风险较低；该模型对工业和制造业公司最为可靠，对银行等金融类公司参考意义较弱。
利润表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 营收 | 1.72B | 1.84B | 2.15B | 2.83B | 2.89B | 2.95B | 2.89B | 3.07B |
| 毛利润 | 545.40M | 605.70M | 767.80M | 1.18B | 1.14B | 1.13B | 998.50M | 1.10B |
| 销售及管理费用 | 262.90M | 272.70M | 302.00M | 362.80M | 316.90M | 353.40M | 338.50M | 393.60M |
| 研发费用 | 40.30M | 38.90M | 46.90M | 52.80M | 58.50M | 68.40M | 69.10M | 74.30M |
| 营业利润 | 242.20M | 298.80M | 418.90M | 760.20M | 760.80M | 707.40M | 590.90M | 636.10M |
| 税前利润 | 240.70M | 291.80M | 401.30M | 748.90M | 679.90M | 698.00M | 585.50M | 600.90M |
| 税费 | 41.40M | 59.00M | 72.50M | 107.20M | 114.70M | 122.30M | 107.50M | 121.60M |
| 净利润 | 206.90M | 241.70M | 346.20M | 661.80M | 585.90M | 593.40M | 492.70M | 493.70M |
| 基本每股收益 | 3 | 3 | 5 | 9 | 8 | 8 | 7 | 7 |
| 稀释每股收益 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 | 6.69 | 6.79 |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 营收 | 698.00M | 766.50M | 804.60M | 805.00M | 844.90M | 872.30M |
| 毛利润 | 231.90M | 273.90M | 294.30M | 303.90M | 296.40M | 329.20M |
| 销售及管理费用 | 88.00M | 95.90M | 102.70M | 107.00M | 99.50M | 117.60M |
| 研发费用 | 16.30M | 19.10M | 17.10M | 21.80M | 15.80M | 19.70M |
| 营业利润 | 127.60M | 158.90M | 174.50M | 175.10M | 181.10M | 191.90M |
| 税前利润 | 110.50M | 157.00M | 171.90M | 161.50M | 180.10M | 180.10M |
| 税费 | 24.10M | 30.20M | 34.00M | 33.30M | 44.70M | 32.20M |
| 净利润 | 89.80M | 131.80M | 140.00M | 132.10M | 138.80M | 154.00M |
| 基本每股收益 | 1 | 2 | 2 | 2 | 2 | 2 |
| 稀释每股收益 | 1.23 | 1.82 | 1.92 | 1.82 | 1.92 | 2.15 |
资产负债表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 流动资产总额 | 894.40M | 1.06B | 1.37B | 1.74B | 1.92B | 1.94B | 1.54B | 1.98B |
| 现金及短期投资 | 337.40M | 439.10M | 615.50M | 762.60M | 894.30M | 853.90M | 484.60M | 791.30M |
| 存货 | 214.50M | 235.70M | 321.30M | 378.40M | 414.80M | 434.70M | 377.00M | 443.90M |
| 总资产 | 1.98B | 2.34B | 2.79B | 3.31B | 3.62B | 3.83B | 3.64B | 4.27B |
| 流动负债总额 | 283.70M | 341.60M | 503.40M | 594.10M | 519.00M | 671.80M | 550.40M | 654.90M |
| 短期负债 | 100.00K | 11.90M | 12.40M | 53.50M | 18.20M | 151.70M | 17.90M | 22.70M |
| 长期负债 | 196.00M | 255.00M | 252.90M | 208.80M | 206.70M | 72.80M | 202.60M | 202.80M |
| 总负债 | 582,600,000.00 | 768,200,000.00 | 939,300,000.00 | 978,400,000.00 | 931,900,000.00 | 948,500,000.00 | 961,100,000.00 | 1,094,000,000.00 |
| 股东权益总额 | 1.40B | 1.57B | 1.85B | 2.34B | 2.68B | 2.88B | 2.68B | 3.18B |
| 留存收益 | 1.35B | 1.55B | 1.85B | 2.46B | 2.99B | 3.52B | 3.96B | 4.37B |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 流动资产总额 | 1.46B | 1.68B | 1.82B | 1.98B | 1.83B | 1.81B |
| 现金及短期投资 | 404.20M | 509.70M | 628.50M | 791.30M | 521.40M | 435.80M |
| 存货 | 388.70M | 421.10M | 438.00M | 443.90M | 452.60M | 447.40M |
| 总资产 | 3.62B | 3.95B | 4.11B | 4.27B | 4.11B | 4.08B |
| 流动负债总额 | 526.70M | 604.60M | 635.40M | 654.90M | 674.00M | 640.50M |
| 短期负债 | 21.80M | 20.90M | 21.40M | 22.70M | 21.40M | 20.90M |
| 长期负债 | 202.60M | 202.60M | 202.70M | 202.80M | 202.80M | 202.90M |
| 总负债 | 935,100,000.00 | 1,023,700,000.00 | 1,054,300,000.00 | 1,094,000,000.00 | 1,119,400,000.00 | 1,086,200,000.00 |
| 股东权益总额 | 2.68B | 2.93B | 3.05B | 3.18B | 2.99B | 2.99B |
| 留存收益 | 4.03B | 4.14B | 4.26B | 4.37B | 4.48B | 4.62B |
现金流量表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 经营活动现金流 | 288.60M | 367.20M | 472.50M | 584.00M | 724.00M | 776.50M | 653.40M | 754.80M |
| 折旧与摊销 | 104.40M | 103.40M | 109.10M | 122.30M | 120.60M | 137.30M | 155.40M | 171.40M |
| 自由现金流 | 183.90M | 240.80M | 298.10M | 330.60M | 439.40M | 414.50M | 276.40M | 468.90M |
| 已派股息 | -42.10M | -45.10M | -48.10M | -51.10M | -54.10M | -57.00M | -59.10M | -61.20M |
| 股票回购/发行 | -70.80M | -85.30M | -121.40M | -151.90M | -222.20M | -451.20M | -566.60M | -136.80M |
| 期末现金余额 | 337.40M | 439.10M | 615.50M | 762.60M | 894.30M | 853.90M | 484.60M | 791.30M |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 经营活动现金流 | 129.40M | 177.10M | 197.20M | 251.10M | 89.90M | 124.00M |
| 折旧与摊销 | 40.00M | 41.40M | 43.00M | 47.00M | 45.20M | 46.20M |
| 自由现金流 | 58.10M | 101.90M | 133.90M | 175.00M | 47.20M | 80.80M |
| 已派股息 | -15.20M | -15.10M | -15.10M | -15.80M | -15.80M | -15.70M |
| 股票回购/发行 | -136.00M | -500.00K | -100.00K | -200.00K | -300.10M | -156.70M |
| 期末现金余额 | 404.20M | 509.70M | 628.50M | 791.30M | 521.40M | 435.80M |
回报与效率指标
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 净资产收益率i | 15.46 | 16.28 | 20.20 | 31.59 | 23.34 | 21.32 | 17.71 | 16.85 |
| 总资产收益率i | 10.77 | 11.19 | 13.48 | 21.67 | 16.91 | 15.94 | 13.19 | 12.48 |
| 投入资本回报率i | 13.82 | 14.05 | 17.23 | 27.60 | 20.77 | 18.66 | 15.52 | 14.82 |
| 5年平均净资产收益率i | 12.95 | 13.48 | 15.59 | 19.22 | 21.37 | 22.55 | 22.83 | 22.16 |
| 息税前利润率i | 14.50 | 16.32 | 19.07 | 26.74 | 23.82 | 23.97 | 20.34 | 19.56 |
| 自由现金流/营收i | 10.71 | 13.09 | 13.89 | 11.68 | 15.22 | 14.05 | 9.55 | 15.25 |
| 流动比率i | 3.15 | 3.10 | 2.73 | 2.93 | 3.70 | 2.88 | 2.79 | 3.02 |
| 速动比率i | 2.21 | 2.22 | 1.99 | 2.11 | 2.70 | 2.03 | 1.88 | 2.09 |
| 资产负债率i | 9.91 | 14.06 | 11.66 | 9.82 | 8.79 | 8.07 | 8.30 | 7.52 |
| 长期负债权益比i | 14.04 | 20.18 | 16.89 | 11.64 | 11.16 | 5.46 | 10.60 | 9.40 |
| 利息保障倍数i | 29.65 | 35.33 | 49.94 | 92.33 | 87.06 | 78.56 | 196.17 | 1,202.80 |
| 营收复合年增长率(3年)i | 7.05 | 6.83 | 10.32 | 18.14 | 16.20 | 11.17 | 0.72 | 2.12 |
| 净利润复合年增长率(3年)i | 29.35 | 18.95 | 31.95 | 47.34 | 34.33 | 19.68 | -9.37 | -5.55 |
| 自由现金流复合年增长率(3年)i | 31.54 | 69.78 | 31.03 | 21.59 | 22.20 | 11.61 | -5.79 | 2.19 |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 净资产收益率i | 17.42 | 17.72 | 16.94 | 16.85 | 19.13 | 19.09 |
| 总资产收益率i | 12.94 | 13.11 | 12.64 | 12.48 | 14.05 | 14.07 |
| 投入资本回报率i | 15.22 | 15.51 | 14.92 | 14.82 | 16.83 | 16.95 |
| 5年平均净资产收益率i | -- | -- | -- | -- | -- | -- |
| 息税前利润率i | 19.70 | 20.18 | 20.02 | 19.56 | 20.88 | 20.98 |
| 自由现金流/营收i | 10.60 | 11.62 | 12.56 | 15.25 | 14.22 | 13.13 |
| 流动比率i | 2.77 | 2.78 | 2.87 | 3.02 | 2.71 | 2.82 |
| 速动比率i | 1.80 | 1.81 | 1.97 | 2.09 | 1.79 | 1.79 |
| 资产负债率i | 8.38 | 7.67 | 7.25 | 7.52 | 7.69 | 7.66 |
| 长期负债权益比i | 10.49 | 9.64 | 9.05 | 9.40 | 9.86 | 9.74 |
| 利息保障倍数i | 316.89 | 1,493.25 | -6,042.00 | 1,202.80 | 336.25 | 155.13 |
| 营收复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
| 净利润复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
| 自由现金流复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
✦ 量化营收集中度 计算方式说明
单一主业
- 在披露的2个业务分部中，Proprietary products是最大的一项，占营收的82.84%。
- 第二大业务West Vantage占比仅17.16%，与第一名差距悬殊——若主业大幅放缓，几乎没有其他业务能够对冲。
营收构成 最近报告期
业务分部
Proprietary products82.84%
West Vantage17.16%
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
西部制药服务 讨论区 0 条评论